PMID- 35419733
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20220531
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 30
IP  - 7
DP  - 2022 Jul
TI  - Combined analysis of clinical and laboratory markers to predict the risk of 
      venous thromboembolism in patients with IDH1 wild-type glioblastoma.
PG  - 6063-6069
LID - 10.1007/s00520-022-07050-1 [doi]
AB  - PURPOSE: We have combined analysis of clinical and laboratory markers to try to 
      find an optimal model to predict venous thromboembolism in isocitrate 
      dehydrogenase 1 (IDH1) wild-type glioblastoma (GBM) by a prospective research. 
      METHODS: Patients with newly histologically confirmed IDH1 wild-type (IDH1wt) GBM 
      were recruited for this study. Status of IDH1, PTEN, P53, BRAF, MGMT promoter 
      methylation (MGMTp), and TERT promoter (TERTp) was determined using genetic 
      sequencing through polymerase chain reaction (PCR). Amplification of EGFR was 
      established through fluorescence in situ hybridization (FISH). Competing risk 
      regression model was performed to calculate the risk of VTE. Clinical and 
      laboratory parameters that were independently predicted risk of VTE were used to 
      develop a risk assessment model (RAM). RESULTS: One hundred thirty-one patients 
      with IDH1wt GBM were included in the present analysis. A total of 48/131 patients 
      (36.6%) developed VTE. D-dimer, ECOG score, and EGFR amplification were suggested 
      to be significantly associated with the VTE risk in multivariable analysis. High 
      ECOG score (>2), high D-dimer (>1.6 mug/ml), and EGFR amplification were used as 
      the strongest independent predictors of increased risk of VTE. The cumulative 
      incidence of VTE was 17.2% for patients with score 0 (n =29), 23.6% for patients 
      with score 1 (n =55), and 63.8% for patients with score 2 (n = 35) or score 3 (n 
      = 12) by application of a RAM. CONCLUSIONS: In IDH1wt GBM patients, by applying a 
      VTE risk assessment model, we could identify patients with a very high and low 
      risk of VTE.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Huang, Yong
AU  - Huang Y
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan 
      University, Shuiguohu street, 168 Donghu road, Wuhan, Hubei, China.
AD  - Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, Hubei, China.
FAU - Ding, Haixia
AU  - Ding H
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan 
      University, Shuiguohu street, 168 Donghu road, Wuhan, Hubei, China.
AD  - Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, Hubei, China.
FAU - Luo, Min
AU  - Luo M
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan 
      University, Shuiguohu street, 168 Donghu road, Wuhan, Hubei, China.
AD  - Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, Hubei, China.
FAU - Li, Sirui
AU  - Li S
AD  - Department of Radiology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, 
      China.
FAU - Xie, Conghua
AU  - Xie C
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan 
      University, Shuiguohu street, 168 Donghu road, Wuhan, Hubei, China.
AD  - Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, Hubei, China.
FAU - Zhong, Yahua
AU  - Zhong Y
AUID- ORCID: 0000-0003-2573-1080
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan 
      University, Shuiguohu street, 168 Donghu road, Wuhan, Hubei, China. 
      doctorzyh73@163.com.
AD  - Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, Hubei, China. 
      doctorzyh73@163.com.
FAU - Li, Zhiqiang
AU  - Li Z
AD  - Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220413
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Biomarkers)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Biomarkers
MH  - *Brain Neoplasms/pathology
MH  - ErbB Receptors/genetics
MH  - *Glioblastoma/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Isocitrate Dehydrogenase/genetics
MH  - Mutation
MH  - Prospective Studies
MH  - *Venous Thromboembolism/etiology/genetics
OTO - NOTNLM
OT  - Glioblastoma
OT  - Markers
OT  - Risk assessment model
OT  - Venous thromboembolism
EDAT- 2022/04/15 06:00
MHDA- 2022/05/31 06:00
CRDT- 2022/04/14 05:23
PHST- 2021/07/14 00:00 [received]
PHST- 2022/04/06 00:00 [accepted]
PHST- 2022/04/15 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2022/04/14 05:23 [entrez]
AID - 10.1007/s00520-022-07050-1 [pii]
AID - 10.1007/s00520-022-07050-1 [doi]
PST - ppublish
SO  - Support Care Cancer. 2022 Jul;30(7):6063-6069. doi: 10.1007/s00520-022-07050-1. 
      Epub 2022 Apr 13.